

Luisa Mestroni

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7715300/publications.pdf>

Version: 2024-02-01

199
papers

12,941
citations

25034

57
h-index

24982

109
g-index

226
all docs

226
docs citations

226
times ranked

11675
citing authors

#	ARTICLE	IF	CITATIONS
1	An <i>LMNA</i> synonymous variant associated with severe dilated cardiomyopathy: Case report. American Journal of Medical Genetics, Part A, 2022, 188, 600-605.	1.2	1
2	Association of Titin Variations With Late-Onset Dilated Cardiomyopathy. JAMA Cardiology, 2022, 7, 371.	6.1	18
3	Activation of PDGFRA signaling contributes to filamin C-related arrhythmogenic cardiomyopathy. Science Advances, 2022, 8, eabk0052.	10.3	12
4	Atomic Force Microscopy (AFM) Applications in Arrhythmogenic Cardiomyopathy. International Journal of Molecular Sciences, 2022, 23, 3700.	4.1	11
5	The response to cardiac resynchronization therapy in <scp>LMNA</scp> cardiomyopathy. European Journal of Heart Failure, 2022, 24, 685-693.	7.1	7
6	AFM macro-probes to investigate whole 3D cardiac spheroids. Micro and Nano Engineering, 2022, 15, 100134.	2.9	2
7	Regulation of extracellular matrix composition by fibroblasts during perinatal cardiac maturation. Journal of Molecular and Cellular Cardiology, 2022, 169, 84-95.	1.9	7
8	Precision medicine in laminopathies: insights from the REDLAMINA registry. Revista Espanola De Cardiologia (English Ed), 2021, 74, 208-209.	0.6	0
9	Induction of ADAM10 by Radiation Therapy Drives Fibrosis, Resistance, and Epithelial-to-Mesenchymal Transition in Pancreatic Cancer. Cancer Research, 2021, 81, 3255-3269.	0.9	37
10	Genetics of dilated cardiomyopathy. Current Opinion in Cardiology, 2021, 36, 288-294.	1.8	21
11	Medicina de precisión aplicada a laminopatías: enseñanzas del registro REDLAMINA. Revista Espanola De Cardiologia, 2021, 74, 208-209.	1.2	0
12	Experiences with Diagnosis and Treatment of Chagas Disease at a United States Teaching Hospital—Clinical Features of Patients with Positive Screening Serologic Testing. Tropical Medicine and Infectious Disease, 2021, 6, 93.	2.3	4
13	HDAC Inhibition Reverses Preexisting Diastolic Dysfunction and Blocks Covert Extracellular Matrix Remodeling. Circulation, 2021, 143, 1874-1890.	1.6	71
14	The genetic architecture of Plakophilin 2 cardiomyopathy. Genetics in Medicine, 2021, 23, 1961-1968.	2.4	13
15	Microfabricated cantilevers for parallelized cell-cell adhesion measurements. European Biophysics Journal, 2021, , 1.	2.2	3
16	Antiarrhythmic therapy and risk of cumulative ventricular arrhythmias in arrhythmogenic right ventricle cardiomyopathy. International Journal of Cardiology, 2021, 334, 58-64.	1.7	13
17	Prevalence and evolution of right ventricular dysfunction among different genetic backgrounds in dilated cardiomyopathy. Canadian Journal of Cardiology, 2021, 37, 1743-1750.	1.7	6
18	The Sarcomeric Spring Protein Titin: Biophysical Properties, Molecular Mechanisms, and Genetic Mutations Associated with Heart Failure and Cardiomyopathy. Current Cardiology Reports, 2021, 23, 121.	2.9	18

#	ARTICLE	IF	CITATIONS
19	Compromised Biomechanical Properties, Cellâ€“Cell Adhesion and Nanotubes Communication in Cardiac Fibroblasts Carrying the Lamin A/C D192G Mutation. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9193.	4.1	5
20	Valsartan in early-stage hypertrophic cardiomyopathy: a randomized phase 2 trial. <i>Nature Medicine</i> , 2021, 27, 1818-1824.	30.7	51
21	Phenotypic Expression, Natural History, and Risk Stratification of Cardiomyopathy Caused by Filamin C Truncating Variants. <i>Circulation</i> , 2021, 144, 1600-1611.	1.6	43
22	Mechanisms and Insights for the Development of Heart Failure Associated with Cancer Therapy. <i>Children</i> , 2021, 8, 829.	1.5	2
23	The Arrhythmic Phenotype in Cardiomyopathy. <i>Heart Failure Clinics</i> , 2021, 18, 101-113.	2.1	0
24	Mortality risk in chronic Chagas cardiomyopathy: a systematic review and metaâ€“analysis. <i>ESC Heart Failure</i> , 2021, 8, 5466-5481.	3.1	12
25	Clinical and genetic features of arrhythmogenic cardiomyopathy: Diagnosis, management and the heart failure perspective. <i>Progress in Pediatric Cardiology</i> , 2021, 63, 101459.	0.4	2
26	Myocardial Strain and Association With Clinical Outcomes in Danon Disease: A Model for Monitoring Progression of Genetic Cardiomyopathies. <i>Journal of the American Heart Association</i> , 2021, 10, e022544.	3.7	5
27	125â€“Sex differences in myocarditis natural history. <i>European Heart Journal Supplements</i> , 2021, 23, .	0.1	0
28	382â€“Clinical manifestation and prognosis of different cardiomyopathies on the base of genetic background (GEN-PHEN). <i>European Heart Journal Supplements</i> , 2021, 23, .	0.1	0
29	Abstract 12210: Long-Term Efficacy and Safety of ARRY-371797 (PF-0765803) in an Open-Label Rollover Study in Patients With Dilated Cardiomyopathy Due to a Lamin A/C Gene Mutation. <i>Circulation</i> , 2021, 144, .	1.6	2
30	Nanomaterials for Cardiac Tissue Engineering. <i>Molecules</i> , 2020, 25, 5189.	3.8	37
31	Apical Sparing Strain Pattern in Danon Disease. <i>JACC: Cardiovascular Imaging</i> , 2020, 13, 2689-2691.	5.3	6
32	Danon Disease-Associated LAMP-2 Deficiency Drives Metabolic Signature Indicative of Mitochondrial Aging and Fibrosis in Cardiac Tissue and hiPSC-Derived Cardiomyocytes. <i>Journal of Clinical Medicine</i> , 2020, 9, 2457.	2.4	12
33	Current Understanding of the Role of Cytoskeletal Cross-Linkers in the Onset and Development of Cardiomyopathies. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5865.	4.1	7
34	Modifications of Titin Contribute to the Progression of Cardiomyopathy and Represent a Therapeutic Target for Treatment of Heart Failure. <i>Journal of Clinical Medicine</i> , 2020, 9, 2770.	2.4	16
35	Early Lethality Due to a Novel Desmoplakin Variant Causing Infantile Epidermolysis Bullosa Simplex With Fragile Skin, Aplasia Cutis Congenita, and Arrhythmogenic Cardiomyopathy. <i>Circulation Genomic and Precision Medicine</i> , 2020, 13, e002800.	3.6	9
36	Viscoelastic behavior of cardiomyocytes carrying LMNA mutations. <i>Biorheology</i> , 2020, 57, 1-14.	0.4	6

#	ARTICLE	IF	CITATIONS
37	Understanding the role of titin in dilated cardiomyopathy. <i>International Journal of Cardiology</i> , 2020, 316, 186-187.	1.7	2
38	<i>FLNC</i> truncations cause arrhythmogenic right ventricular cardiomyopathy. <i>Journal of Medical Genetics</i> , 2020, 57, 254-257.	3.2	43
39	Transcriptome signature of ventricular arrhythmia in dilated cardiomyopathy reveals increased fibrosis and activated TP53. <i>Journal of Molecular and Cellular Cardiology</i> , 2020, 139, 124-134.	1.9	17
40	Altered microtubule structure, hemichannel localization and beating activity in cardiomyocytes expressing pathologic nuclear lamin A/C. <i>Heliyon</i> , 2020, 6, e03175.	3.2	14
41	The electrocardiogram in the diagnosis and management of patients with dilated cardiomyopathy. <i>European Journal of Heart Failure</i> , 2020, 22, 1097-1107.	7.1	52
42	Contemporary survival trends and aetiological characterization in non-ischaemic dilated cardiomyopathy. <i>European Journal of Heart Failure</i> , 2020, 22, 1111-1121.	7.1	54
43	Arrhythmogenic right ventricular cardiomyopathy: evaluation of the current diagnostic criteria and differential diagnosis. <i>European Heart Journal</i> , 2020, 41, 1414-1429.	2.2	239
44	Cardiac disorders. , 2020, , 109-125.		0
45	Abstract 15707: Histone Deacetylase Inhibition Reverses Preexisting Diastolic Dysfunction and Blocks Covert Extracellular Matrix Remodeling. <i>Circulation</i> , 2020, 142, .	1.6	0
46	2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy: Executive summary. <i>Heart Rhythm</i> , 2019, 16, e373-e407.	0.7	135
47	Genetic Risk of Arrhythmic Phenotypes in Patients With Dilated Cardiomyopathy. <i>Journal of the American College of Cardiology</i> , 2019, 74, 1480-1490.	2.8	167
48	DNA Damage Response/TP53 Pathway Is Activated and Contributes to the Pathogenesis of Dilated Cardiomyopathy Associated With LMNA (Lamin A/C) Mutations. <i>Circulation Research</i> , 2019, 124, 856-873.	4.5	95
49	2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy. <i>Heart Rhythm</i> , 2019, 16, e301-e372.	0.7	494
50	Genetics of Dilated Cardiomyopathy: Current Knowledge and Future Perspectives. , 2019, , 45-69.		3
51	Historical Terminology, Classifications, and Present Definition of DCM. , 2019, , 1-9.		3
52	Gold Nanoparticle-Functionalized Reverse Thermal Gel for Tissue Engineering Applications. <i>ACS Applied Materials & Interfaces</i> , 2019, 11, 18671-18680.	8.0	47
53	Regional Variation in <i>RBM20</i> Causes a Highly Penetrant Arrhythmogenic Cardiomyopathy. <i>Circulation: Heart Failure</i> , 2019, 12, e005371.	3.9	96
54	Genotype-phenotype correlations in ARVC: Toward a precision medicine approach. <i>International Journal of Cardiology</i> , 2019, 286, 115-116.	1.7	1

#	ARTICLE	IF	CITATIONS
55	Genomic Reorganization of Lamin-Associated Domains in Cardiac Myocytes Is Associated With Differential Gene Expression and DNA Methylation in Human Dilated Cardiomyopathy. <i>Circulation Research</i> , 2019, 124, 1198-1213.	4.5	72
56	Fruit and Vegetable Concentrate Supplementation and Cardiovascular Health: A Systematic Review from a Public Health Perspective. <i>Journal of Clinical Medicine</i> , 2019, 8, 1914.	2.4	1
57	Knock Down of Plakophilin 2 Dysregulates Adhesion Pathway through Upregulation of miR200b and Alters the Mechanical Properties in Cardiac Cells. <i>Cells</i> , 2019, 8, 1639.	4.1	18
58	The Giant Protein Titin's Role in Cardiomyopathy: Genetic, Transcriptional, and Post-translational Modifications of TTN and Their Contribution to Cardiac Disease. <i>Frontiers in Physiology</i> , 2019, 10, 1436.	2.8	77
59	Lamin A/C Cardiomyopathy: Implications for Treatment. <i>Current Cardiology Reports</i> , 2019, 21, 160.	2.9	17
60	Baseline Characteristics of the VANISH Cohort. <i>Circulation: Heart Failure</i> , 2019, 12, e006231.	3.9	10
61	Ankyrin-B dysfunction predisposes to arrhythmogenic cardiomyopathy and is amenable to therapy. <i>Journal of Clinical Investigation</i> , 2019, 129, 3171-3184.	8.2	42
62	Biomechanical defects and rescue of cardiomyocytes expressing pathologic nuclear lamins. <i>Cardiovascular Research</i> , 2018, 114, 846-857.	3.8	34
63	Arrhythmogenic Cardiomyopathy. <i>Circulation</i> , 2018, 137, 1611-1613.	1.6	14
64	Filamin C Truncation Mutations Are Associated With Arrhythmogenic Dilated Cardiomyopathy and Changes in the Cell's Cell Adhesion Structures. <i>JACC: Clinical Electrophysiology</i> , 2018, 4, 504-514.	3.2	125
65	Cellular biomechanics impairment in keratinocytes is associated with a C-terminal truncated desmoplakin: An atomic force microscopy investigation. <i>Micron</i> , 2018, 106, 27-33.	2.2	8
66	Genetic Infiltrative Cardiomyopathies. <i>Heart Failure Clinics</i> , 2018, 14, 215-224.	2.1	14
67	Modeling Cardiomyopathy and Arrhythmias in Induced Pluripotent Stem Cell-Derived Cardiomyocytes. <i>Circulation Genomic and Precision Medicine</i> , 2018, 11, e002088.	3.6	0
68	Transcriptome analysis of human heart failure reveals dysregulated cell adhesion in dilated cardiomyopathy and activated immune pathways in ischemic heart failure. <i>BMC Genomics</i> , 2018, 19, 812.	2.8	150
69	3D Carbon-Nanotube-Based Composites for Cardiac Tissue Engineering. <i>ACS Applied Bio Materials</i> , 2018, 1, 1530-1537.	4.6	57
70	Injectable Hydrogels for Cardiac Tissue Engineering. <i>Macromolecular Bioscience</i> , 2018, 18, e1800079.	4.1	172
71	Genetics of Dilated Cardiomyopathy: Clinical Implications. <i>Current Cardiology Reports</i> , 2018, 20, 83.	2.9	33
72	The S-wave angle identifies arrhythmogenic right ventricular cardiomyopathy in patients with electrocardiographically concealed disease phenotype. <i>Journal of Electrocardiology</i> , 2018, 51, 1003-1008.	0.9	1

#	ARTICLE	IF	CITATIONS
73	Molecular and Cellular Mechanisms in Heart Failure. , 2018, , 3-19.		9
74	Multilevel analyses of SCN5A mutations in arrhythmogenic right ventricular dysplasia/cardiomyopathy suggest non-canonical mechanisms for disease pathogenesis. Cardiovascular Research, 2017, 113, 102-111.	3.8	148
75	The Burden of Early Phenotypes and the Influence of Wall Thickness in Hypertrophic Cardiomyopathy Mutation Carriers. JAMA Cardiology, 2017, 2, 419.	6.1	50
76	Association between mutation status and left ventricular reverse remodelling in dilated cardiomyopathy. Heart, 2017, 103, 1704-1710.	2.9	64
77	Danon disease for the cardiologist: case report and review of the literature. Journal of Community Hospital Internal Medicine Perspectives, 2017, 7, 107-114.	0.8	18
78	Unraveling Missing Genes and Missing Inheritance in Arrhythmogenic Cardiomyopathy. Circulation: Arrhythmia and Electrophysiology, 2017, 10, .	4.8	1
79	Dilated Cardiomyopathy. Circulation Research, 2017, 121, 731-748.	4.5	527
80	Injectable Carbon Nanotube-Functionalized Reverse Thermal Gel Promotes Cardiomyocytes Survival and Maturation. ACS Applied Materials & Interfaces, 2017, 9, 31645-31656.	8.0	52
81	Biomarkers of cardiovascular stress and fibrosis in preclinical hypertrophic cardiomyopathy. Open Heart, 2017, 4, e000615.	2.3	22
82	Right precordial-directed electrocardiographical markers identify arrhythmogenic right ventricular cardiomyopathy in the absence of conventional depolarization or repolarization abnormalities. BMC Cardiovascular Disorders, 2017, 17, 261.	1.7	3
83	Diseases of the Nuclear Membrane. , 2017, , 233-248.		1
84	Association of Phenotype and Genotype in the Diagnosis and Prognosis of ARVC/D in the Adult Population. , 2016, , 89-103.		0
85	A Review of the Giant Protein Titin in Clinical Molecular Diagnostics of Cardiomyopathies. Frontiers in Cardiovascular Medicine, 2016, 3, 21.	2.4	90
86	Improving the appropriateness of sudden arrhythmic death primary prevention by implantable cardioverter-defibrillator therapy in patients with low left ventricular ejection fraction. Point of view. Journal of Cardiovascular Medicine, 2016, 17, 245-255.	1.5	16
87	Natural History of Dilated Cardiomyopathy in Children. Journal of the American Heart Association, 2016, 5, .	3.7	39
88	The cell-stretcher: A novel device for the mechanical stimulation of cell populations. Review of Scientific Instruments, 2016, 87, 084301.	1.3	17
89	Danon disease “ dysregulation of autophagy in a multisystem disorder with cardiomyopathy. Journal of Cell Science, 2016, 129, 2135-43.	2.0	69
90	Biomimetic Polymers for Cardiac Tissue Engineering. Biomacromolecules, 2016, 17, 1593-1601.	5.4	37

#	ARTICLE	IF	CITATIONS
91	FLNC Gene Splice Mutations Cause Dilated Cardiomyopathy. JACC Basic To Translational Science, 2016, 1, 344-359.	4.1	87
92	Early Arrhythmic Events in Idiopathic Dilated Cardiomyopathy. JACC: Clinical Electrophysiology, 2016, 2, 535-543.	3.2	24
93	In Hypertrophic Cardiomyopathy, the Spatial Peaks <scp>QRS</scp> Angle Identifies Those With Sustained Ventricular Arrhythmias. Clinical Cardiology, 2016, 39, 459-463.	1.8	16
94	Obscurin Variants in Patients With Left Ventricular Noncompaction. Journal of the American College of Cardiology, 2016, 68, 2237-2238.	2.8	26
95	Risk Stratification in Arrhythmic Right Ventricular Cardiomyopathy Without Implantable Cardioverter-Defibrillators. JACC: Clinical Electrophysiology, 2016, 2, 558-564.	3.2	23
96	Pediatric Cardiomyopathy. Journal of the American College of Cardiology, 2016, 67, 526-528.	2.8	4
97	Easy fabrication of aligned PLLA nanofibers-based 2D scaffolds suitable for cell contact guidance studies. Materials Science and Engineering C, 2016, 62, 301-306.	7.3	13
98	Clinical Spectrum of <i>PRKAG2</i> Syndrome. Circulation: Arrhythmia and Electrophysiology, 2016, 9, e003121.	4.8	90
99	The Cardiomyopathy Lamin A/C D192G Mutation Disrupts Whole-Cell Biomechanics in Cardiomyocytes as Measured by Atomic Force Microscopy Loading-Unloading Curve Analysis. Scientific Reports, 2015, 5, 13388.	3.3	44
100	Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC). Respiratory Medicine, 2015, , 337-360.	0.1	0
101	Role of Titin Missense Variants in Dilated Cardiomyopathy. Journal of the American Heart Association, 2015, 4, .	3.7	64
102	Analysis of long- and short-range contribution to adhesion work in cardiac fibroblasts: An atomic force microscopy study. Materials Science and Engineering C, 2015, 49, 217-224.	7.3	6
103	Arrhythmogenic Phenotype in Dilated Cardiomyopathy: Natural History and Predictors of Life-Threatening Arrhythmias. Journal of the American Heart Association, 2015, 4, e002149.	3.7	102
104	Diagnosis, prevalence, and screening of familial dilated cardiomyopathy. Expert Opinion on Orphan Drugs, 2015, 3, 869-876.	0.8	54
105	AFM single-cell force spectroscopy links altered nuclear and cytoskeletal mechanics to defective cell adhesion in cardiac myocytes with a nuclear lamin mutation. Nucleus, 2015, 6, 394-407.	2.2	27
106	Abstract 19804: The Spatial QRS-T Angle Predicts Ventricular Arrhythmias in Patients With Hypertrophic Cardiomyopathy. Circulation, 2015, 132, .	1.6	0
107	Decreased Levels of BAG3 in a Family With a Rare Variant and in Idiopathic Dilated Cardiomyopathy. Journal of Cellular Physiology, 2014, 229, 1697-1702.	4.1	68
108	Genetic causes of dilated cardiomyopathy. Progress in Pediatric Cardiology, 2014, 37, 13-18.	0.4	78

#	ARTICLE	IF	CITATIONS
109	Pharmacogenetics of heart failure. <i>Current Opinion in Cardiology</i> , 2014, 29, 227-234.	1.8	6
110	Carbon Nanotube Facilitation of Myocardial Ablation with Radiofrequency Energy. <i>Journal of Cardiovascular Electrophysiology</i> , 2014, 25, 1385-1390.	1.7	25
111	Titin and desmosomal genes in the natural history of arrhythmogenic right ventricular cardiomyopathy. <i>Journal of Medical Genetics</i> , 2014, 51, 669-676.	3.2	41
112	Family Members of Patients With ARVC. <i>Journal of the American College of Cardiology</i> , 2014, 64, 302-303.	2.8	4
113	Danon Disease. <i>Circulation: Heart Failure</i> , 2014, 7, 843-849.	3.9	162
114	Inhibition of Proto-Oncogene c-Src Tyrosine Kinase. <i>Journal of the American College of Cardiology</i> , 2014, 63, 935-937.	2.8	2
115	Exploring the elasticity and adhesion behavior of cardiac fibroblasts by atomic force microscopy indentation. <i>Materials Science and Engineering C</i> , 2014, 40, 427-434.	7.3	23
116	Arrhythmogenic right ventricular cardiomyopathy: From genetics to diagnostic and therapeutic challenges. <i>World Journal of Cardiology</i> , 2014, 6, 1234.	1.5	36
117	Arrhythmogenic Right Ventricular Cardiomyopathy: Clinical Assessment and Differential Diagnosis. , 2014, , 139-149.		0
118	Genetics: Genotype/Phenotype Correlations in Cardiomyopathies. , 2014, , 13-24.		0
119	Genetics and Genomics for the Prevention and Treatment of Cardiovascular Disease: Update. <i>Circulation</i> , 2013, 128, 2813-2851.	1.6	100
120	Carbon Nanotubes Instruct Physiological Growth and Functionally Mature Syncytia: Nongenetic Engineering of Cardiac Myocytes. <i>ACS Nano</i> , 2013, 7, 5746-5756.	14.6	105
121	Atomic force microscopy of 3T3 and SW-13 cell lines: An investigation of cell elasticity changes due to fixation. <i>Materials Science and Engineering C</i> , 2013, 33, 3303-3308.	7.3	30
122	Cardiac Hypertrophy, Accessory Pathway, and Conduction System Disease in an Adolescent. <i>Journal of the American College of Cardiology</i> , 2013, 62, e17.	2.8	19
123	Poor Prognosis of Rare Sarcomeric Gene Variants in Patients with Dilated Cardiomyopathy. <i>Clinical and Translational Science</i> , 2013, 6, 424-428.	3.1	52
124	Whole Exome Sequencing Identifies a Troponin T Mutation Hot Spot in Familial Dilated Cardiomyopathy. <i>PLoS ONE</i> , 2013, 8, e78104.	2.5	29
125	Improving cardiac myocytes performance by carbon nanotubes platforms. <i>Frontiers in Physiology</i> , 2013, 4, 239.	2.8	51
126	The Role of Clinical Observation: Red Flag 7 Syndrome and Multi-system Cardiomyopathies. , 2013, , 73-111.		0

#	ARTICLE	IF	CITATIONS
127	Clinical Genetic Testing in Cardiomyopathies. , 2013, , 119-124.		0
128	Family History. , 2013, , 19-24.		0
129	Genetics and genetic testing of dilated cardiomyopathy: a new perspective. <i>Discovery Medicine</i> , 2013, 15, 43-9.	0.5	31
130	Truncations of Titin Causing Dilated Cardiomyopathy. <i>New England Journal of Medicine</i> , 2012, 366, 619-628.	27.0	1,147
131	Utility of Cardiac Magnetic Resonance Imaging to Differentiate Cardiac Sarcoidosis from Arrhythmogenic Right Ventricular Cardiomyopathy. <i>American Journal of Cardiology</i> , 2012, 110, 575-579.	1.6	73
132	Carbon Nanotubes Promote Growth and Spontaneous Electrical Activity in Cultured Cardiac Myocytes. <i>Nano Letters</i> , 2012, 12, 1831-1838.	9.1	196
133	Sudden Death Associated With Danon Disease in Women. <i>American Journal of Cardiology</i> , 2012, 109, 406-411.	1.6	58
134	SCN5A Mutations Associate With Arrhythmic Dilated Cardiomyopathy and Commonly Localize to the Voltage-Sensing Mechanism. <i>Journal of the American College of Cardiology</i> , 2011, 57, 2160-2168.	2.8	197
135	Hearing the Noise. <i>Journal of the American College of Cardiology</i> , 2011, 57, 2328-2329.	2.8	9
136	Tafazzin Gene Mutations Are Uncommon Causes of Dilated Cardiomyopathy in Adults. <i>Neurology International</i> , 2011, 1, e4.	0.5	4
137	High-throughput Genotyping Robot-assisted Method for Mutation Detection in Patients With Hypertrophic Cardiomyopathy. <i>Diagnostic Molecular Pathology</i> , 2011, 20, 175-179.	2.1	18
138	Genetic Variation in Titin in Arrhythmogenic Right Ventricular Cardiomyopathyâ€œOverlap Syndromes. <i>Circulation</i> , 2011, 124, 876-885.	1.6	263
139	Prognostic predictors in arrhythmogenic right ventricular cardiomyopathy: results from a 10-year registry. <i>European Heart Journal</i> , 2011, 32, 1105-1113.	2.2	121
140	Heart failure and personalized medicine. <i>Journal of Cardiovascular Medicine</i> , 2011, 12, 6-12.	1.5	10
141	Pharmacogenomics, personalized medicine, and heart failure. <i>Discovery Medicine</i> , 2011, 11, 551-61.	0.5	13
142	Prognostic impact of familial screening in dilated cardiomyopathy. <i>European Journal of Heart Failure</i> , 2010, 12, 922-927.	7.1	51
143	Genetic Evaluation of Cardiomyopathyâ€œA Heart Failure Society of America Practice Guideline. <i>Journal of Cardiac Failure</i> , 2009, 15, 83-97.	1.7	523
144	Pharmacogenetic effect of an endothelin-1 haplotype on response to bucindolol therapy in chronic heart failure. <i>Pharmacogenetics and Genomics</i> , 2009, 19, 35-43.	1.5	28

#	ARTICLE	IF	CITATIONS
145	Are Nonsustained Ventricular Tachycardias Predictive of Major Arrhythmias in Patients with Dilated Cardiomyopathy on Optimal Medical Treatment?. PACE - Pacing and Clinical Electrophysiology, 2008, 31, 290-299.	1.2	46
146	Lamin A/C Gene and the Heart. Journal of the American College of Cardiology, 2008, 52, 1261-1262.	2.8	23
147	Cardiomyopathy and carnitine deficiency. Molecular Genetics and Metabolism, 2008, 94, 162-166.	1.1	60
148	The challenge of cardiomyopathies in 2007. Journal of Cardiovascular Medicine, 2008, 9, 545-554.	1.5	10
149	Is the long term outcome of familial dilated cardiomyopathy different with respect to sporadic forms. European Journal of Heart Failure, Supplement, 2008, 7, 40-40.	0.0	0
150	Prevalence of Desmin Mutations in Dilated Cardiomyopathy. Circulation, 2007, 115, 1244-1251.	1.6	176
151	Genetics of dilated cardiomyopathy conduction disease. Progress in Pediatric Cardiology, 2007, 24, 3-13.	0.4	9
152	Danon disease presenting with dilated cardiomyopathy and a complex phenotype. Journal of Human Genetics, 2007, 52, 830-835.	2.3	65
153	Cardiomyopathy, familial dilated. Orphanet Journal of Rare Diseases, 2006, 1, 27.	2.7	137
154	Ophthalmic Manifestations of Danon Disease. Ophthalmology, 2006, 113, 1010-1013.	5.2	77
155	Thymopoietin (lamina-associated polypeptide 2) gene mutation associated with dilated cardiomyopathy. Human Mutation, 2005, 26, 566-574.	2.5	167
156	Î±-Myosin Heavy Chain. Circulation, 2005, 112, 54-59.	1.6	204
157	SCN5A Mutation Associated With Dilated Cardiomyopathy, Conduction Disorder, and Arrhythmia. Circulation, 2004, 110, 2163-2167.	1.6	412
158	Drug Therapy in the Heart Transplant Recipient. Circulation, 2004, 110, 3858-3865.	1.6	200
159	Analysis of Genetic Variations of Lamin A/C Gene (LMNA) by Denaturing High-Performance Liquid Chromatography. Journal of Biomolecular Screening, 2004, 9, 625-628.	2.6	10
160	Familial hypertrophic cardiomyopathy: clinical features, molecular genetics and molecular genetic testing. Expert Review of Molecular Diagnostics, 2004, 4, 99-113.	3.1	34
161	Natural history of dilated cardiomyopathy due to lamin A/C gene mutations. Journal of the American College of Cardiology, 2003, 41, 771-780.	2.8	411
162	Familial Dilated Cardiomyopathy. Circulation, 2003, 108, e118-21.	1.6	16

#	ARTICLE	IF	CITATIONS
163	149 Familial dilated cardiomyopathy: an international registry. <i>European Journal of Heart Failure, Supplement</i> , 2003, 2, 25-26.	0.0	0
164	Estimating the frequency of familial dilated cardiomyopathy in the presence of misclassification errors. <i>Journal of Applied Statistics</i> , 2001, 28, 53-62.	1.3	14
165	Current perspective new insights into the molecular basis of familial dilated cardiomyopathy. <i>Italian Heart Journal: Official Journal of the Italian Federation of Cardiology</i> , 2001, 2, 280-6.	0.1	5
166	Lamin A/C Gene Mutation Associated With Dilated Cardiomyopathy With Variable Skeletal Muscle Involvement. <i>Circulation</i> , 2000, 101, 473-476.	1.6	311
167	Cardiomyopathy: Genetics in muscular dystrophies. , 2000, , 81-84.		0
168	Dilated Cardiomyopathy and Arrhythmogenic Right Ventricular Dysplasia: From Gene to Phenotype. <i>Developments in Cardiovascular Medicine</i> , 2000, , 19-26.	0.1	0
169	Guidelines for the study of familial dilated cardiomyopathies. <i>European Heart Journal</i> , 1999, 20, 93-102.	2.2	380
170	Long-term effects of carvedilol in idiopathic dilated cardiomyopathy with persistent left ventricular dysfunction despite chronic metoprolol. <i>Journal of the American College of Cardiology</i> , 1999, 33, 1926-1934.	2.8	122
171	Familial dilated cardiomyopathy. <i>Journal of the American College of Cardiology</i> , 1999, 34, 181-190.	2.8	304
172	Epidemiology of cardiac actin gene mutations in dilated cardiomyopathy. <i>Journal of Cardiac Failure</i> , 1999, 5, 23.	1.7	5
173	ADVANCES IN MOLECULAR GENETICS OF DILATED CARDIOMYOPATHY. <i>Cardiology Clinics</i> , 1998, 16, 611-621.	2.2	11
174	Dilated Cardiomyopathy: Does Etiological Heterogeneity Portend Clinical Heterogeneity?. , 1998, , 160-170.		0
175	The Classification of Cardiomyopathies. , 1998, , 3-13.		0
176	Dystrophin gene abnormalities in two patients with idiopathic dilated cardiomyopathy. <i>Heart</i> , 1997, 78, 608-612.	2.9	76
177	Dilated cardiomyopathy: a genetic approach.. <i>Heart</i> , 1997, 77, 185-188.	2.9	4
178	Molecular genetics of dilated cardiomyopathy. <i>Current Opinion in Cardiology</i> , 1997, 12, 303-309.	1.8	30
179	A New Locus for Arrhythmogenic Right Ventricular Dysplasia on the Long Arm of Chromosome 14. <i>Genomics</i> , 1996, 31, 193-200.	2.9	184
180	A Point Mutation in the 5' Splice Site of the Dystrophin Gene First Intron Responsible for X-Linked Dilated Cardiomyopathy. <i>Human Molecular Genetics</i> , 1996, 5, 73-79.	2.9	164

#	ARTICLE	IF	CITATIONS
181	Molecular genetics of dilated cardiomyopathies. <i>European Heart Journal</i> , 1995, 16, 5-9.	2.2	10
182	A mutation in the dystrophin gene selectively affecting dystrophin expression in the heart.. <i>Journal of Clinical Investigation</i> , 1995, 96, 693-699.	8.2	106
183	Linkage of familial dilated cardiomyopathy to chromosome 9. Heart Muscle Disease Study Group. <i>American Journal of Human Genetics</i> , 1995, 57, 846-52.	6.2	93
184	Familial dilated cardiomyopathy. <i>Heart</i> , 1994, 72, S35-S41.	2.9	52
185	Absence of linkage between idiopathic dilated cardiomyopathy and candidate genes involved in the immune function in a large Italian pedigree.. <i>Journal of Medical Genetics</i> , 1994, 31, 766-771.	3.2	8
186	Low frequency of detection by nested polymerase chain reaction of enterovirus ribonucleic acid in endomyocardial tissue of patients with idiopathic dilated cardiomyopathy. <i>Journal of the American College of Cardiology</i> , 1994, 24, 1033-1040.	2.8	74
187	Evidence from family studies for autoimmunity in dilated cardiomyopathy. <i>Lancet, The</i> , 1994, 344, 773-777.	13.7	159
188	Parental origin of the X chromosome in a patient with a Robertsonian translocation and Turner's syndrome.. <i>Journal of Medical Genetics</i> , 1994, 31, 255-256.	3.2	9
189	Idiopathic left ventricular aneurysm: a clinical and pathological study of a new entity in the spectrum of cardiomyopathies. <i>Postgraduate Medical Journal</i> , 1994, 70 Suppl 1, S13-20.	1.8	3
190	Molecular genetics of dilated cardiomyopathy. <i>Herz</i> , 1994, 19, 97-104.	1.1	9
191	Nested polymerase chain reaction for high-sensitivity detection of enteroviral RNA in biological samples. <i>Journal of Clinical Microbiology</i> , 1993, 31, 1345-1349.	3.9	87
192	Natural History of Idiopathic Dilated Cardiomyopathy. , 1993, , 26-42.		1
193	Beta-adrenergic neuroeffector abnormalities in the failing human heart are produced by local rather than systemic mechanisms.. <i>Journal of Clinical Investigation</i> , 1992, 89, 803-815.	8.2	285
194	Clinical and pathologic study of familial dilated cardiomyopathy. <i>American Journal of Cardiology</i> , 1990, 65, 1449-1453.	1.6	72
195	Correlation between histomorphometric findings on endomyocardial biopsy and clinical findings in idiopathic dilated cardiomyopathy. <i>American Journal of Cardiology</i> , 1989, 64, 504-506.	1.6	22
196	Ventricular arrhythmias in dilated cardiomyopathy: Efficacy of amiodarone. <i>American Heart Journal</i> , 1987, 113, 707-715.	2.7	95
197	Arrhythmias in dilated cardiomyopathy. <i>Postgraduate Medical Journal</i> , 1986, 62, 593-597.	1.8	30
198	Vasodilators in left ventricular failure. <i>Giornale Italiano Di Cardiologia</i> , 1984, 14, 685-93.	0.2	0

#	ARTICLE	IF	CITATIONS
199	Ventricular Arrhythmias in Congestive Cardiomyopathy. New England Journal of Medicine, 1983, 309, 377-378.	27.0	10